Home＞ACADEMIA
JSNP Finalizes Evidence-Based Guidelines for Treatment of Schizophrenia(Sep.28.2015)
(LOG IN FOR FULL STORY)
-
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020 Apr.23
- Expert Cautions against Hasty Discussions on Cost Effective Assessments Apr.20
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President Apr.19
-
Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
Apr.19
-
Lynparza Desirable for Use in Early-Stage Maintenance Therapy: Jikei Univ. Prof.
Apr.02
- Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts(Apr.23)
- Japan Ethical Drug Sales in 54 Fields Shrink 1.6% in 2017(Apr.23)
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020(Apr.23)
- Takeda Sweetens Bid for Shire, Ups Cash Component(Apr.23)
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
